APO Research
Talk to an analyst

APO RESEARCH · REPORT

In Vivo Pharmacology Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global In Vivo Pharmacology Service Market Outlook and Growth Opportunities 2026

3 May 2026193 pages

Choose your research edition.

Industry ResearchIn Vivo Pharmacology Service Industry Research Report 2026140 pages · $2,950 USDIndustry Growth & TrendsGlobal In Vivo Pharmacology Service Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal In Vivo Pharmacology Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal In Vivo Pharmacology Service Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal In Vivo Pharmacology Service Market Analysis and Forecast 2026-2032183 pages · $4,950 USD

Market perspective

The global In Vivo Pharmacology Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for In Vivo Pharmacology Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for In Vivo Pharmacology Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for In Vivo Pharmacology Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the In Vivo Pharmacology Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the In Vivo Pharmacology Service market include NuChem Sciences Inc, Eurofins Discovery, Oncodesign Services, Jubilant Biosys, Pharmaron, Melior Discovery, NUVISAN GmbH, Porsolt and Sygnature Discovery, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global In Vivo Pharmacology Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of In Vivo Pharmacology Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents In Vivo Pharmacology Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global In Vivo Pharmacology Service market.

In Vivo Pharmacology Service Segment by Company

NuChem Sciences Inc

Eurofins Discovery

Oncodesign Services

Jubilant Biosys

Pharmaron

Melior Discovery

NUVISAN GmbH

Porsolt

Sygnature Discovery

Aurigene Pharmaceutical Services Ltd

Reaction Biology

Addexbio

Paraza Pharma, Inc

Aragen Life Sciences Ltd

Dalriada

Biocytogen

Charles River Laboratories

Pharmacelsu

HitGen Inc

TCG Lifesciences

In Vivo Pharmacology Service Segment by Type

Small Molecule Screening

Large Molecule Screening

Others

In Vivo Pharmacology Service Segment by Application

Neurological Diseases

Cardiovascular and Metabolic Diseases

Skin Diseases

Others

In Vivo Pharmacology Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global In Vivo Pharmacology Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the In Vivo Pharmacology Service key companies, revenue, market share, and recent developments.

3. To split the In Vivo Pharmacology Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions In Vivo Pharmacology Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify In Vivo Pharmacology Service significant trends, drivers, influence factors in global and regions.

6. To analyze In Vivo Pharmacology Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global In Vivo Pharmacology Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of In Vivo Pharmacology Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of In Vivo Pharmacology Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global In Vivo Pharmacology Service industry.

Chapter 3: Detailed analysis of In Vivo Pharmacology Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of In Vivo Pharmacology Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of In Vivo Pharmacology Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. In Vivo Pharmacology Service Industry Trends Table 2. In Vivo Pharmacology Service Industry Drivers Table 3. In Vivo Pharmacology Service Industry Opportunities and Challenges Table 4. In Vivo Pharmacology Service Industry Restraints Table 5. Global In Vivo Pharmacology Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global In Vivo Pharmacology Service Revenue Share by Company (2021-2026) Table 7. Global In Vivo Pharmacology Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global In Vivo Pharmacology Service Key Company Manufacturing Base & Headquarters Table 9. Global In Vivo Pharmacology Service Company, Product Type & Application Table 10. Global In Vivo Pharmacology Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global In Vivo Pharmacology Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Small Molecule Screening Table 15. Significant Companies of Large Molecule Screening Table 16. Significant Companies of Others Table 17. Global In Vivo Pharmacology Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global In Vivo Pharmacology Service Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global In Vivo Pharmacology Service Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global In Vivo Pharmacology Service Sales Value Share by Type (2021-2026) Table 21. Global In Vivo Pharmacology Service Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Neurological Diseases Table 23. Significant Companies of Cardiovascular and Metabolic Diseases Table 24. Significant Companies of Skin Diseases Table 25. Significant Companies of Others Table 26. Global In Vivo Pharmacology Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global In Vivo Pharmacology Service Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global In Vivo Pharmacology Service Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global In Vivo Pharmacology Service Sales Value Share by Application (2021-2026) Table 30. Global In Vivo Pharmacology Service Sales Value Share by Application (2027-2032) Table 31. Global In Vivo Pharmacology Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global In Vivo Pharmacology Service Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global In Vivo Pharmacology Service Sales Value Share by Region (2021-2026) Table 34. Global In Vivo Pharmacology Service Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global In Vivo Pharmacology Service Sales Value Share by Region (2027-2032) Table 36. Global In Vivo Pharmacology Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global In Vivo Pharmacology Service Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global In Vivo Pharmacology Service Sales Value Market Share by Country (2021-2026) Table 39. Global In Vivo Pharmacology Service Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global In Vivo Pharmacology Service Sales Value Market Share by Country (2027-2032) Table 41. NuChem Sciences Inc Company Information Table 42. NuChem Sciences Inc Business Overview Table 43. NuChem Sciences Inc In Vivo Pharmacology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. NuChem Sciences Inc In Vivo Pharmacology Service Product Portfolio Table 45. NuChem Sciences Inc Recent Development Table 46. Eurofins Discovery Company Information Table 47. Eurofins Discovery Business Overview Table 48. Eurofins Discovery In Vivo Pharmacology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Eurofins Discovery In Vivo Pharmacology Service Product Portfolio Table 50. Eurofins Discovery Recent Development Table 51. Oncodesign Services Company Information Table 52. Oncodesign Services Business Overview Table 53. Oncodesign Services In Vivo Pharmacology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Oncodesign Services In Vivo Pharmacology Service Product Portfolio Table 55. Oncodesign Services Recent Development Table 56. Jubilant Biosys Company Information Table 57. Jubilant Biosys Business Overview Table 58. Jubilant Biosys In Vivo Pharmacology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Jubilant Biosys In Vivo Pharmacology Service Product Portfolio Table 60. Jubilant Biosys Recent Development Table 61. Pharmaron Company Information Table 62. Pharmaron Business Overview Table 63. Pharmaron In Vivo Pharmacology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Pharmaron In Vivo Pharmacology Service Product Portfolio Table 65. Pharmaron Recent Development Table 66. Melior Discovery Company Information Table 67. Melior Discovery Business Overview Table 68. Melior Discovery In Vivo Pharmacology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Melior Discovery In Vivo Pharmacology Service Product Portfolio Table 70. Melior Discovery Recent Development Table 71. NUVISAN GmbH Company Information Table 72. NUVISAN GmbH Business Overview Table 73. NUVISAN GmbH In Vivo Pharmacology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. NUVISAN GmbH In Vivo Pharmacology Service Product Portfolio Table 75. NUVISAN GmbH Recent Development Table 76. Porsolt Company Information Table 77. Porsolt Business Overview Table 78. Porsolt In Vivo Pharmacology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Porsolt In Vivo Pharmacology Service Product Portfolio Table 80. Porsolt Recent Development Table 81. Sygnature Discovery Company Information Table 82. Sygnature Discovery Business Overview Table 83. Sygnature Discovery In Vivo Pharmacology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Sygnature Discovery In Vivo Pharmacology Service Product Portfolio Table 85. Sygnature Discovery Recent Development Table 86. Aurigene Pharmaceutical Services Ltd Company Information Table 87. Aurigene Pharmaceutical Services Ltd Business Overview Table 88. Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Service Product Portfolio Table 90. Aurigene Pharmaceutical Services Ltd Recent Development Table 91. Reaction Biology Company Information Table 92. Reaction Biology Business Overview Table 93. Reaction Biology In Vivo Pharmacology Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Reaction Biology In Vivo Pharmacology Service Product Portfolio Table 95. Reaction Biology Recent Development Table 96. Addexbio Company Information Table 97. Addexbio Business Overview Table 98. Addexbio In Vivo Pharmacology Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Addexbio In Vivo Pharmacology Service Product Portfolio Table 100. Addexbio Recent Development Table 101. Paraza Pharma, Inc Company Information Table 102. Paraza Pharma, Inc Business Overview Table 103. Paraza Pharma, Inc In Vivo Pharmacology Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Paraza Pharma, Inc In Vivo Pharmacology Service Product Portfolio Table 105. Paraza Pharma, Inc Recent Development Table 106. Aragen Life Sciences Ltd Company Information Table 107. Aragen Life Sciences Ltd Business Overview Table 108. Aragen Life Sciences Ltd In Vivo Pharmacology Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Aragen Life Sciences Ltd In Vivo Pharmacology Service Product Portfolio Table 110. Aragen Life Sciences Ltd Recent Development Table 111. Dalriada Company Information Table 112. Dalriada Business Overview Table 113. Dalriada In Vivo Pharmacology Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Dalriada In Vivo Pharmacology Service Product Portfolio Table 115. Dalriada Recent Development Table 116. Biocytogen Company Information Table 117. Biocytogen Business Overview Table 118. Biocytogen In Vivo Pharmacology Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Biocytogen In Vivo Pharmacology Service Product Portfolio Table 120. Biocytogen Recent Development Table 121. Charles River Laboratories Company Information Table 122. Charles River Laboratories Business Overview Table 123. Charles River Laboratories In Vivo Pharmacology Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Charles River Laboratories In Vivo Pharmacology Service Product Portfolio Table 125. Charles River Laboratories Recent Development Table 126. Pharmacelsu Company Information Table 127. Pharmacelsu Business Overview Table 128. Pharmacelsu In Vivo Pharmacology Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Pharmacelsu In Vivo Pharmacology Service Product Portfolio Table 130. Pharmacelsu Recent Development Table 131. HitGen Inc Company Information Table 132. HitGen Inc Business Overview Table 133. HitGen Inc In Vivo Pharmacology Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. HitGen Inc In Vivo Pharmacology Service Product Portfolio Table 135. HitGen Inc Recent Development Table 136. TCG Lifesciences Company Information Table 137. TCG Lifesciences Business Overview Table 138. TCG Lifesciences In Vivo Pharmacology Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. TCG Lifesciences In Vivo Pharmacology Service Product Portfolio Table 140. TCG Lifesciences Recent Development Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. In Vivo Pharmacology Service Product Image Figure 2. Global In Vivo Pharmacology Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global In Vivo Pharmacology Service Market Size (2021-2032) & (US$ Million) Figure 4. Global In Vivo Pharmacology Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Small Molecule Screening Image Figure 8. Large Molecule Screening Image Figure 9. Others Image Figure 10. Global In Vivo Pharmacology Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global In Vivo Pharmacology Service Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global In Vivo Pharmacology Service Sales Value Share by Type (2021-2032) Figure 13. Neurological Diseases Image Figure 14. Cardiovascular and Metabolic Diseases Image Figure 15. Skin Diseases Image Figure 16. Others Image Figure 17. Global In Vivo Pharmacology Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global In Vivo Pharmacology Service Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global In Vivo Pharmacology Service Sales Value Share by Application (2021-2032) Figure 20. Global In Vivo Pharmacology Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global In Vivo Pharmacology Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America In Vivo Pharmacology Service Sales Value (2021-2032) & (US$ Million) Figure 23. North America In Vivo Pharmacology Service Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe In Vivo Pharmacology Service Sales Value (2021-2032) & (US$ Million) Figure 25. Europe In Vivo Pharmacology Service Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific In Vivo Pharmacology Service Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific In Vivo Pharmacology Service Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America In Vivo Pharmacology Service Sales Value (2021-2032) & (US$ Million) Figure 29. South America In Vivo Pharmacology Service Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa In Vivo Pharmacology Service Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa In Vivo Pharmacology Service Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecule Screening
  • Large Molecule Screening
  • Others
Applications
  • Neurological Diseases
  • Cardiovascular and Metabolic Diseases
  • Skin Diseases
  • Others
Companies covered
  • NuChem Sciences Inc
  • Eurofins Discovery
  • Oncodesign Services
  • Jubilant Biosys
  • Pharmaron
  • Melior Discovery
  • NUVISAN GmbH
  • Porsolt
  • Sygnature Discovery
  • Aurigene Pharmaceutical Services Ltd
  • Reaction Biology
  • Addexbio
  • Paraza Pharma, Inc
  • Aragen Life Sciences Ltd
  • Dalriada
  • Biocytogen
  • Charles River Laboratories
  • Pharmacelsu
  • HitGen Inc
  • TCG Lifesciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global In Vivo Pharmacology Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global In Vivo Pharmacology Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 In Vivo Pharmacology Service Market Dynamics
  1. 2.1 In Vivo Pharmacology Service Industry Trends
  2. 2.2 In Vivo Pharmacology Service Industry Drivers
  3. 2.3 In Vivo Pharmacology Service Industry Opportunities and Challenges
  4. 2.4 In Vivo Pharmacology Service Industry Restraints
3 In Vivo Pharmacology Service Market by Company
  1. 3.1 Global In Vivo Pharmacology Service Company Revenue Ranking in 2025
  2. 3.2 Global In Vivo Pharmacology Service Revenue by Company (2021-2026)
  3. 3.3 Global In Vivo Pharmacology Service Company Ranking (2024-2026)
  4. 3.4 Global In Vivo Pharmacology Service Company Manufacturing Base and Headquarters
  5. 3.5 Global In Vivo Pharmacology Service Company Product Type and Application
  6. 3.6 Global In Vivo Pharmacology Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global In Vivo Pharmacology Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 In Vivo Pharmacology Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 In Vivo Pharmacology Service Market by Type
  1. 4.1 In Vivo Pharmacology Service Type Introduction
  2. 4.1.1 Small Molecule Screening
  3. 4.1.2 Large Molecule Screening
  4. 4.1.3 Others
  5. 4.2 Global In Vivo Pharmacology Service Sales Value by Type
  6. 4.2.1 Global In Vivo Pharmacology Service Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global In Vivo Pharmacology Service Sales Value by Type (2021-2032)
  8. 4.2.3 Global In Vivo Pharmacology Service Sales Value Share by Type (2021-2032)
5 In Vivo Pharmacology Service Market by Application
  1. 5.1 In Vivo Pharmacology Service Application Introduction
  2. 5.1.1 Neurological Diseases
  3. 5.1.2 Cardiovascular and Metabolic Diseases
  4. 5.1.3 Skin Diseases
  5. 5.1.4 Others
  6. 5.2 Global In Vivo Pharmacology Service Sales Value by Application
  7. 5.2.1 Global In Vivo Pharmacology Service Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global In Vivo Pharmacology Service Sales Value by Application (2021-2032)
  9. 5.2.3 Global In Vivo Pharmacology Service Sales Value Share by Application (2021-2032)
6 In Vivo Pharmacology Service Regional Value Analysis
  1. 6.1 Global In Vivo Pharmacology Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global In Vivo Pharmacology Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global In Vivo Pharmacology Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global In Vivo Pharmacology Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America In Vivo Pharmacology Service Sales Value (2021-2032)
  7. 6.3.2 North America In Vivo Pharmacology Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe In Vivo Pharmacology Service Sales Value (2021-2032)
  10. 6.4.2 Europe In Vivo Pharmacology Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific In Vivo Pharmacology Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific In Vivo Pharmacology Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America In Vivo Pharmacology Service Sales Value (2021-2032)
  16. 6.6.2 South America In Vivo Pharmacology Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa In Vivo Pharmacology Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa In Vivo Pharmacology Service Sales Value Share by Country, 2025 VS 2032
7 In Vivo Pharmacology Service Country-level Value Analysis
  1. 7.1 Global In Vivo Pharmacology Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global In Vivo Pharmacology Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global In Vivo Pharmacology Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global In Vivo Pharmacology Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt In Vivo Pharmacology Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt In Vivo Pharmacology Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt In Vivo Pharmacology Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 NuChem Sciences Inc
  2. 8.1.1 NuChem Sciences Inc Company Information
  3. 8.1.2 NuChem Sciences Inc Business Overview
  4. 8.1.3 NuChem Sciences Inc In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 NuChem Sciences Inc In Vivo Pharmacology Service Product Portfolio
  6. 8.1.5 NuChem Sciences Inc Recent Developments
  7. 8.2 Eurofins Discovery
  8. 8.2.1 Eurofins Discovery Company Information
  9. 8.2.2 Eurofins Discovery Business Overview
  10. 8.2.3 Eurofins Discovery In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eurofins Discovery In Vivo Pharmacology Service Product Portfolio
  12. 8.2.5 Eurofins Discovery Recent Developments
  13. 8.3 Oncodesign Services
  14. 8.3.1 Oncodesign Services Company Information
  15. 8.3.2 Oncodesign Services Business Overview
  16. 8.3.3 Oncodesign Services In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Oncodesign Services In Vivo Pharmacology Service Product Portfolio
  18. 8.3.5 Oncodesign Services Recent Developments
  19. 8.4 Jubilant Biosys
  20. 8.4.1 Jubilant Biosys Company Information
  21. 8.4.2 Jubilant Biosys Business Overview
  22. 8.4.3 Jubilant Biosys In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Jubilant Biosys In Vivo Pharmacology Service Product Portfolio
  24. 8.4.5 Jubilant Biosys Recent Developments
  25. 8.5 Pharmaron
  26. 8.5.1 Pharmaron Company Information
  27. 8.5.2 Pharmaron Business Overview
  28. 8.5.3 Pharmaron In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pharmaron In Vivo Pharmacology Service Product Portfolio
  30. 8.5.5 Pharmaron Recent Developments
  31. 8.6 Melior Discovery
  32. 8.6.1 Melior Discovery Company Information
  33. 8.6.2 Melior Discovery Business Overview
  34. 8.6.3 Melior Discovery In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Melior Discovery In Vivo Pharmacology Service Product Portfolio
  36. 8.6.5 Melior Discovery Recent Developments
  37. 8.7 NUVISAN GmbH
  38. 8.7.1 NUVISAN GmbH Company Information
  39. 8.7.2 NUVISAN GmbH Business Overview
  40. 8.7.3 NUVISAN GmbH In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 NUVISAN GmbH In Vivo Pharmacology Service Product Portfolio
  42. 8.7.5 NUVISAN GmbH Recent Developments
  43. 8.8 Porsolt
  44. 8.8.1 Porsolt Company Information
  45. 8.8.2 Porsolt Business Overview
  46. 8.8.3 Porsolt In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Porsolt In Vivo Pharmacology Service Product Portfolio
  48. 8.8.5 Porsolt Recent Developments
  49. 8.9 Sygnature Discovery
  50. 8.9.1 Sygnature Discovery Company Information
  51. 8.9.2 Sygnature Discovery Business Overview
  52. 8.9.3 Sygnature Discovery In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sygnature Discovery In Vivo Pharmacology Service Product Portfolio
  54. 8.9.5 Sygnature Discovery Recent Developments
  55. 8.10 Aurigene Pharmaceutical Services Ltd
  56. 8.10.1 Aurigene Pharmaceutical Services Ltd Company Information
  57. 8.10.2 Aurigene Pharmaceutical Services Ltd Business Overview
  58. 8.10.3 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Service Product Portfolio
  60. 8.10.5 Aurigene Pharmaceutical Services Ltd Recent Developments
  61. 8.11 Reaction Biology
  62. 8.11.1 Reaction Biology Company Information
  63. 8.11.2 Reaction Biology Business Overview
  64. 8.11.3 Reaction Biology In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Reaction Biology In Vivo Pharmacology Service Product Portfolio
  66. 8.11.5 Reaction Biology Recent Developments
  67. 8.12 Addexbio
  68. 8.12.1 Addexbio Company Information
  69. 8.12.2 Addexbio Business Overview
  70. 8.12.3 Addexbio In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Addexbio In Vivo Pharmacology Service Product Portfolio
  72. 8.12.5 Addexbio Recent Developments
  73. 8.13 Paraza Pharma, Inc
  74. 8.13.1 Paraza Pharma, Inc Company Information
  75. 8.13.2 Paraza Pharma, Inc Business Overview
  76. 8.13.3 Paraza Pharma, Inc In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Paraza Pharma, Inc In Vivo Pharmacology Service Product Portfolio
  78. 8.13.5 Paraza Pharma, Inc Recent Developments
  79. 8.14 Aragen Life Sciences Ltd
  80. 8.14.1 Aragen Life Sciences Ltd Company Information
  81. 8.14.2 Aragen Life Sciences Ltd Business Overview
  82. 8.14.3 Aragen Life Sciences Ltd In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Aragen Life Sciences Ltd In Vivo Pharmacology Service Product Portfolio
  84. 8.14.5 Aragen Life Sciences Ltd Recent Developments
  85. 8.15 Dalriada
  86. 8.15.1 Dalriada Company Information
  87. 8.15.2 Dalriada Business Overview
  88. 8.15.3 Dalriada In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Dalriada In Vivo Pharmacology Service Product Portfolio
  90. 8.15.5 Dalriada Recent Developments
  91. 8.16 Biocytogen
  92. 8.16.1 Biocytogen Company Information
  93. 8.16.2 Biocytogen Business Overview
  94. 8.16.3 Biocytogen In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Biocytogen In Vivo Pharmacology Service Product Portfolio
  96. 8.16.5 Biocytogen Recent Developments
  97. 8.17 Charles River Laboratories
  98. 8.17.1 Charles River Laboratories Company Information
  99. 8.17.2 Charles River Laboratories Business Overview
  100. 8.17.3 Charles River Laboratories In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Charles River Laboratories In Vivo Pharmacology Service Product Portfolio
  102. 8.17.5 Charles River Laboratories Recent Developments
  103. 8.18 Pharmacelsu
  104. 8.18.1 Pharmacelsu Company Information
  105. 8.18.2 Pharmacelsu Business Overview
  106. 8.18.3 Pharmacelsu In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Pharmacelsu In Vivo Pharmacology Service Product Portfolio
  108. 8.18.5 Pharmacelsu Recent Developments
  109. 8.19 HitGen Inc
  110. 8.19.1 HitGen Inc Company Information
  111. 8.19.2 HitGen Inc Business Overview
  112. 8.19.3 HitGen Inc In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  113. 8.19.4 HitGen Inc In Vivo Pharmacology Service Product Portfolio
  114. 8.19.5 HitGen Inc Recent Developments
  115. 8.20 TCG Lifesciences
  116. 8.20.1 TCG Lifesciences Company Information
  117. 8.20.2 TCG Lifesciences Business Overview
  118. 8.20.3 TCG Lifesciences In Vivo Pharmacology Service Revenue and Gross Margin (2021-2026)
  119. 8.20.4 TCG Lifesciences In Vivo Pharmacology Service Product Portfolio
  120. 8.20.5 TCG Lifesciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst